Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 7/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100399 | 0.88 | PRCP (0.56) | PRCPACEHDAC8HDAC3HDAC1 | |
| SCHEMBL12507462 | 0.87 | PRCP (0.55) | PRCPACEHDAC8HDAC3HDAC1 | |
| SCHEMBL9599601 | 0.85 | OPRM1 (0.51) | PRCPACEHDAC8HDAC3HDAC1 | |
| SCHEMBL3609137 | 0.84 | ACE (0.52) | PRCPACEHDAC8HDAC3HDAC1 | |
| SCHEMBL14879190 | 0.84 | PRCP (0.52) | PRCPACEHDAC8HDAC3HDAC1 | |
| SCHEMBL14879169 | 0.83 | PRCP (0.51) | PRCPACEHDAC8HDAC1HDAC2 | |
| SCHEMBL22525235 | 0.80 | PRCP (0.57) | PRCPACEMTNR1B | |
| SCHEMBL2088793 | 0.80 | PRCP (0.57) | PRCPACEMTNR1B | |
| Hydrochloric Acid SCHEMBL2571761 | 0.78 | PRCP (0.55) | PRCPACEMTNR1B | |
| SCHEMBL6369660 | 0.78 | PRCP (0.62) | PRCPMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | PRCP 175/4885ACE 44/4885HDAC8 1325/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | PRCP 175/4885ACE 44/4885HDAC8 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.